Liraglutide (Victoza) vs lixisenatide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Liraglutide (Victoza)
Marketed by Novo Nordisk
NCT00318461 · Phase 3 · completed
This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.
Next expected readout: June 2027 · NCT03883412 (registry estimate)
Reported efficacy
Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)
Result source: NCT00318461
lixisenatide · Adlyxin / Lyxumia
Marketed by Sanofi and partners
NCT00707031 · Phase 3 · completed
The 639 participants were randomly assigned to lixisenatide or active treatment with exenatide, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority criterion, with a between-group difference of 0.17 percentage points and a 95% confidence interval of 0.033 to 0.297, but HbA1c is a surrogate endpoint rather than a hard clinical outcome.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
Reported efficacy
Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054) (met)
Result source: NCT00707031
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Liraglutide (Victoza) | lixisenatide |
|---|---|---|
| HbA1c, change | -0.6% vs 0.4%−1.1 vs placeboNCT0154121527 other results
| -0.6% vs 0.1%−0.6 vs placeboNCT0179870619 other results
|
| Body weight, change (kg) | -2.5 vs -0.9−1.6 vs placeboNCT0154121522 other results
| -0.6 vs 1.0vs Insulin GlulisineNCT0176855917 other results
|
| HbA1c below 7% | 63.7% vs 36.5%+27.2 vs placeboNCT015412153 other results
| 53% vs 38.8%+14.2 vs placeboNCT0116977910 other results
|
| Fasting plasma glucose, change | -1.1 vs 0.8−1.9 vs placeboNCT0154121521 other results
| -0.3 vs 0.0−0.3 vs placeboNCT0179870617 other results
|
| 3-point MACE (% with event) | 13% vs 14.9%−1.9 vs placeboNCT01179048 | —Not reported |
HbA1c, change
- Liraglutide (Victoza)
- -0.6% vs 0.4%−1.1 vs placeboNCT01541215
27 other results
- -1% vs -1.0% NCT00318461
- -0.6% vs -0.5% NCT00318461
- -1.0% vs -1.0% NCT00318461
- -0.6% vs -0.5% NCT00318461
- -0.7% vs -1.0% NCT00318461
- -0.4% vs -0.5% NCT00318461
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -0.7% vs 0.7% NCT01541215
- -2.0% vs -1.7% NCT02501161
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- 7.9% vs 8.9% NCT01505673
- 6.4% vs 6.4% NCT02765399
- -1.1% vs -0.5% NCT01907854
- -1.8% vs -1.2% NCT01973231
- -1.7% vs -1.0% NCT02008682
- 4.1% vs 3.4% NCT01966978
- -1.4% vs -1.1% NCT02730377
- -1.3% vs -0.7% NCT01917656
- -1.1% vs 0.2% NCT00318422
- lixisenatide
- -0.6% vs 0.1%−0.6 vs placeboNCT01798706
19 other results
- -0.8% vs -0.5% NCT01169779
- -0.7% vs -0.4% NCT00975286
- -0.9% vs -0.3% NCT00763815
- -0.7% vs -0.4% NCT00715624
- -0.8% vs -0.1% NCT00713830
- -0.8% vs -0.4% NCT00763451
- -0.9% vs -0.4% NCT00763451
- -0.8% vs 0.1% NCT00866658
- -0.6% vs -0.8% NCT01768559
- -0.8% vs -1.0% NCT00707031
- -1.9% vs -1.7% NCT05413369
- -1.1% vs -0.6% NCT02058160
- -1.6% vs -1.3% NCT02058147
- -0.8% vs -1.3% NCT02058147
- -1.9% vs -1.7% NCT05413369
- -0.7% vs -0.7% NCT00976937
- -1.8% vs -1.6% NCT01476475
- -0.6% vs -0.7% NCT01596504
- -0.3% vs -0.5% NCT01175473
Body weight, change (kg)
- Liraglutide (Victoza)
- -2.5 vs -0.9−1.6 vs placeboNCT01541215
22 other results
- -2.3 vs 1.0 NCT01541215
- -2.8 vs 0.9 NCT00318461
- -2.9 vs 0.7 NCT00318461
- -2.6 vs 0.9 NCT00318461
- -3.0 vs 0.7 NCT00318461
- -1.8 vs 0.9 NCT00318461
- -2.1 vs 0.7 NCT00318461
- 0.2 vs 1.3 NCT03172494
- -2.5 vs 1.3 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 0.5 vs 2.2 NCT02501161
- -0.7 vs 0.7 NCT02911948
- -0.9 vs 2.6 NCT02420262
- -1.4 vs 1.8 NCT01952145
- 2.9 vs 4.1 NCT02607306
- -1 vs 4.1 NCT02607306
- 1.2 vs 3 NCT02501161
- -3.8 vs -3.5 NCT02730377
- -3.3 vs -1.8 NCT01907854
- -4.2 vs -3.7 NCT01973231
- -5.4 vs -1.5 NCT01917656
- -0.6 vs 3.1 NCT01966978
- lixisenatide
- -0.6 vs 1.0vs Insulin GlulisineNCT01768559
17 other results
- -1.5 vs -0.2 NCT01798706
- -1.5 vs -1.2 NCT01169779
- 0.3 vs 1.2 NCT00975286
- -0.2 vs 0.2 NCT00763815
- -1.8 vs -0.5 NCT00715624
- -1.8 vs -0.9 NCT00713830
- -2.7 vs -1.6 NCT00763451
- -2.6 vs -1.6 NCT00763451
- -0.4 vs 0.1 NCT00866658
- -3.0 vs -4.0 NCT00707031
- -0.3 vs 1.2 NCT05413369
- -0.7 vs 0.7 NCT02058160
- -0.3 vs 1.1 NCT02058147
- -2.5 vs -1.2 NCT00976937
- -2.3 vs 1.1 NCT02058147
- -1.0 vs 0.5 NCT01476475
- -1.6 vs -2.4 NCT01596504
HbA1c below 7%
- Liraglutide (Victoza)
- 63.7% vs 36.5%+27.2 vs placeboNCT01541215
3 other results
- 51.8% vs 23.2% NCT02964247
- 76.5% vs 52.6% NCT02008682
- 44% vs 20% NCT01966978
- lixisenatide
- 53% vs 38.8%+14.2 vs placeboNCT01169779
10 other results
- 56.3% vs 38.5% NCT00975286
- 52.3% vs 26.4% NCT00763815
- 28.3% vs 12% NCT00715624
- 36.4% vs 13.5% NCT00713830
- 42.1% vs 24.1% NCT00763451
- 47.4% vs 24.1% NCT00763451
- 35.6% vs 5.2% NCT00866658
- 48.5% vs 49.8% NCT00707031
- 72.5% vs 59.8% NCT05413369
- 40.7% vs 40% NCT00976937
Fasting plasma glucose, change
- Liraglutide (Victoza)
- -1.1 vs 0.8−1.9 vs placeboNCT01541215
21 other results
- -1.6 vs 1.0 NCT01541215
- -1.7 vs -1.3 NCT00318461
- -1.2 vs -0.6 NCT00318461
- -1.6 vs -1.3 NCT00318461
- -1.2 vs -0.6 NCT00318461
- -1.1 vs -1.3 NCT00318461
- -0.8 vs -0.6 NCT00318461
- -3.6 vs -3.5 NCT03172494
- -2.8 vs -2.3 NCT02911948
- -4.1 vs -4.0 NCT02607306
- -2.6 vs -4.0 NCT02607306
- -3.9 vs -3.7 NCT02501161
- -1.9 vs -3.5 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -4.0 vs -3.8 NCT02501161
- 6.4 vs 6.4 NCT02765399
- -2.2 vs -1.2 NCT02730377
- -2.9 vs -1.6 NCT01973231
- -2.3 vs -1.2 NCT02008682
- -0.1 vs 0.1 NCT01917656
- -1.8 vs -0.6 NCT01917656
- lixisenatide
- -0.3 vs 0.0−0.3 vs placeboNCT01798706
17 other results
- -0.7 vs -0.2 NCT01169779
- 0.3 vs 0.5 NCT00975286
- -1.2 vs -0.3 NCT00763815
- -0.6 vs -0.6 NCT00715624
- -1.0 vs -0.4 NCT00713830
- -0.6 vs 0.1 NCT00763451
- -0.5 vs 0.1 NCT00763451
- -0.4 vs 0.3 NCT00866658
- -0.2 vs -0.2 NCT01768559
- -1.2 vs -1.4 NCT00707031
- -3.2 vs -3.5 NCT05413369
- -0.3 vs -0.5 NCT02058160
- -3.5 vs -3.3 NCT02058147
- -0.5 vs -0.7 NCT00976937
- -1.5 vs -3.3 NCT02058147
- -3.4 vs -3.5 NCT01476475
- 0.1 vs 0.1 NCT01596504
3-point MACE (% with event)
- Liraglutide (Victoza)
- 13% vs 14.9%−1.9 vs placeboNCT01179048
- lixisenatide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. Liraglutide (Victoza): 11 of 11 rows · lixisenatide: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Liraglutide (Victoza) Rows use multiple source trials | lixisenatide Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.02% (n=200) @ 32wka,b,c,d NCT02298192 · Phase 3 · registry result, not featured evidence show 1 more dose-2.01% (n=189) @ 32wk NCT02298192 · Phase 3 · registry result, not featured evidence | -0.74% (n=222) @ 24wka,b,c,d NCT01517412 · Phase 3 · registry result, not featured evidence show 1 more dose-0.65% (n=218) @ 24wk NCT01517412 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain responder rate · % of participants | 47.69% (n=195) vs 19.15% (n=94) placebo @ 26wke,b,c Yes NCT02964247 · Phase 3 · registry result, not featured evidence | 22.2% (n=297) vs 9.2% (n=294) Insulin Glulisine @ 26wke,b,c NCT01768559 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7 Without Weight Gain responder rate · % of participants | 47.69% (n=195) vs 19.15% (n=94) placebo @ 26wke,b,c Yes NCT02964247 · Phase 3 · registry result, not featured evidence | 31.2% (n=295) vs 16.7% (n=293) Insulin Glulisine @ 26wke,b,c NCT01768559 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants | 61.7% (n=162) vs 26.3% (n=175) Sitagliptin @ 26wkf,b,c,g NCT02008682 · Phase 4 · registry result, not featured evidence 1 other source trial34.36% (n=195) vs 9.47% (n=95) placebo @ 26wk Yes NCT02964247 · Phase 3 · registry result, not featured evidence | 28.5% (n=295) vs 35.4% (n=297) Exenatide @ 24wkf,b,c,g NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 9 other source trials32.4% (n=185) vs 18.1% (n=188) placebo @ 24wk NCT01169779 · Phase 3 · registry result, not featured evidence 32.1% (n=215) vs 16.3% (n=221) placebo @ 24wk NCT00975286 · Phase 3 · registry result, not featured evidence 28.9% (n=308) vs 10.1% (n=148) placebo @ 24wk NCT00763815 · Phase 3 · registry result, not featured evidence 24% (n=150) vs 26.3% (n=160) Sitagliptin @ 24wk NCT00976937 · Phase 3 · registry result, not featured evidence 14.5% (n=304) vs 3.8% (n=158) placebo @ 24wk NCT00715624 · Phase 3 · registry result, not featured evidence 19.3% (n=544) vs 4.7% (n=274) placebo @ 24wk NCT00713830 · Phase 3 · registry result, not featured evidence 25.6% (n=156) vs 7.6% (n=158) placebo @ 24wk NCT00763451 · Phase 3 · registry result, not featured evidence 20.4% (n=152) vs 7.6% (n=158) placebo @ 24wk NCT00763451 · Phase 3 · registry result, not featured evidence 17.8% (n=146) vs 1.3% (n=154) placebo @ 24wk NCT00866658 · Phase 3 · registry result, not featured evidence |
| PPG Excursion absolute change · mmol/L | -0.428 vs -0.362 placebo mmol/L @ 26wk1.8 mgb,c NCT01541215 · Phase 3 4 other source trials-0.2 vs 0.09 Insulin Degludec mmol/L @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence -0.54 vs 0.09 Insulin Degludec mmol/L @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence -0.28 vs 0.2 Insulin Glargine mmol/L @ 26wk NCT02501161 · Phase 3 · registry result, not featured evidence -0.76 vs 0.7 Insulin Degludec mmol/L @ 26wk NCT02911948 · Phase 3 · registry result, not featured evidence | -3.42 vs -1.59 Insulin Glulisine mmol/L @ 26wkb,c NCT01768559 · Phase 3 · registry result, not featured evidence |
| SMBG 7-point absolute change · mmol/L | -2.384 vs 0.198 placebo mmol/L @ 26wk1.8 mgb,c NCT01541215 · Phase 3 1 other source trial-2.25 vs -1.36 Sitagliptin mmol/L @ 26wk NCT02008682 · Phase 4 · registry result, not featured evidence | -0.784 vs -0.782 Insulin Glulisine mmol/L @ 26wkb,c NCT01768559 · Phase 3 · registry result, not featured evidence |
| Waist Circumference Change absolute change · cm | 2.5 vs 3.4 Insulin Degludec cm @ 52wka,h,b,c,i NCT02607306 · Phase 3 · registry result, not featured evidence show 1 more dose-1.1 vs 3.4 Insulin Degludec cm @ 52wk NCT02607306 · Phase 3 · registry result, not featured evidence | -1.4 vs -1.93 Liraglutide cm @ 8wk20 µgh,b,c,i NCT01596504 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 21.1%1.8 mg dailyj NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results18.3%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 3% NCT01179048 · Phase 3 15.2%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 41.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 55.2%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 6.3% NCT02765399 · Phase 4 · registry result, not featured evidence 22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 8.6% NCT01505673 · Phase 4 · registry result, not featured evidence 7.9% NCT01907854 · Phase 4 · registry result, not featured evidence 5.4% NCT01973231 · Phase 4 · registry result, not featured evidence 14.7% NCT02008682 · Phase 4 · registry result, not featured evidence 15.1% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 16.1%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 55.1% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4% NCT03175120 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 1.5% NCT02964247 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 3.7%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence | 32.5%j NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.2%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 8.3%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 3.5% NCT01147250 · Phase 3 11.3% NCT05114590 · Phase 4 · registry result, not featured evidence 5.8% NCT05413369 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence 10.5%Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence 11.1% NCT02168491 · Phase 3 · registry result, not featured evidence · combination — NCT02058160 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 12.4%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 11.9% NCT01798706 · Phase 3 · registry result, not featured evidence 10.1% NCT01768559 · Phase 3 · registry result, not featured evidence 10.6%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 16%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 8.7% NCT01169779 · Phase 3 · registry result, not featured evidence 13% NCT00975286 · Phase 3 · registry result, not featured evidence 26% NCT00763815 · Phase 3 · registry result, not featured evidence 27.5%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 22.4%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 10.1% NCT00976937 · Phase 3 · registry result, not featured evidence 35.3% NCT00715624 · Phase 3 · registry result, not featured evidence 30.9% NCT00713830 · Phase 3 · registry result, not featured evidence 18.6%Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 24.8%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence —Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 25%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 39.4%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 13.6% NCT00866658 · Phase 3 · registry result, not featured evidence —20 µg NCT01596504 · Phase 2 · registry result, not featured evidence 4.2%20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 6.8% NCT01476475 · Phase 2 · registry result, not featured evidence 2.6% NCT01175473 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 12%1.8 mg dailyj NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.5%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.5%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT01179048 · Phase 3 0%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 — NCT03260881 · Phase 4 · registry result, not featured evidence 7.4% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 7.9%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence — NCT02765399 · Phase 4 · registry result, not featured evidence — NCT01966978 · Phase 4 · registry result, not featured evidence · combination — NCT02014740 · Phase 4 · registry result, not featured evidence — NCT02299388 · Phase 4 · registry result, not featured evidence — NCT01505673 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01973231 · Phase 4 · registry result, not featured evidence — NCT02008682 · Phase 4 · registry result, not featured evidence 6.4% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 8.3%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence — NCT01234649 · Phase 3 · registry result, not featured evidence · combination 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence — NCT02964247 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.2%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence | 14.1%j NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results2.5%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 4.2%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 — NCT01147250 · Phase 3 0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 0.3% NCT05413369 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence 3.9%Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence — NCT02168491 · Phase 3 · registry result, not featured evidence · combination — NCT02058160 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 9%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 8.5% NCT01798706 · Phase 3 · registry result, not featured evidence 5% NCT01768559 · Phase 3 · registry result, not featured evidence 4.9%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 4.4%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 5.6% NCT01169779 · Phase 3 · registry result, not featured evidence 8.5% NCT00975286 · Phase 3 · registry result, not featured evidence 9% NCT00763815 · Phase 3 · registry result, not featured evidence 10.2%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 8.2%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 2.5% NCT00976937 · Phase 3 · registry result, not featured evidence 11.2% NCT00715624 · Phase 3 · registry result, not featured evidence 12.4% NCT00713830 · Phase 3 · registry result, not featured evidence 8.7%Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 11.8%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence —Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 13.9%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 21.2%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 9.1% NCT00866658 · Phase 3 · registry result, not featured evidence —20 µg NCT01596504 · Phase 2 · registry result, not featured evidence 2.1%20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 3.7% NCT01476475 · Phase 2 · registry result, not featured evidence 2.6% NCT01175473 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.6%1.8 mg dailyj NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results10.4%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 49.7% NCT01179048 · Phase 3 13.6%1.8 mg NCT01541215 · Phase 3 13.5%1.8 mg NCT01541215 · Phase 3 4.2%1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 38.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 9.4%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 0% NCT02765399 · Phase 4 · registry result, not featured evidence 11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 2.9% NCT01505673 · Phase 4 · registry result, not featured evidence 3% NCT01907854 · Phase 4 · registry result, not featured evidence 5.9% NCT01973231 · Phase 4 · registry result, not featured evidence 1.6% NCT02008682 · Phase 4 · registry result, not featured evidence 1.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination 0% NCT02889510 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 7.8%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 2.5% NCT02964247 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 5.1%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 0% NCT01937598 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence | 8.2%j NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results0%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 0.8%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 20.6% NCT01147250 · Phase 3 0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 5.2% NCT05413369 · Phase 3 · registry result, not featured evidence 3.9%Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence 10.2%Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence 11.1% NCT02168491 · Phase 3 · registry result, not featured evidence · combination 5.5% NCT02058160 · Phase 3 · registry result, not featured evidence 3.8%Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 3.9%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 4.5% NCT01798706 · Phase 3 · registry result, not featured evidence 3.7% NCT01768559 · Phase 3 · registry result, not featured evidence 3.1%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 3.1%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 1.5% NCT01169779 · Phase 3 · registry result, not featured evidence 7.6% NCT00975286 · Phase 3 · registry result, not featured evidence 7.7% NCT00763815 · Phase 3 · registry result, not featured evidence 10.2%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 8.2%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 1.9% NCT00976937 · Phase 3 · registry result, not featured evidence 14% NCT00715624 · Phase 3 · registry result, not featured evidence 10.1% NCT00713830 · Phase 3 · registry result, not featured evidence —Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 13%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 9.9%Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 2.8%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 6.1%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 6.5% NCT00866658 · Phase 3 · registry result, not featured evidence 2.1%20 µg NCT01596504 · Phase 2 · registry result, not featured evidence —20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 5.6% NCT01476475 · Phase 2 · registry result, not featured evidence 0% NCT01175473 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 1.8 mg dailyj nausea 21.5% diarrhoea 16.5% nasopharyngitis 14.9% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 32 more results1.2 mg daily nausea 17.5% nasopharyngitis 15% headache 14.2% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6 mg daily nasopharyngitis 17.8% diarrhoea 12.8% nausea 12.4% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.8 mg nausea 28.8% (placebo 13.2%) vomiting 25.8% (placebo 8.8%) diarrhoea 22.7% (placebo 16.2%) NCT01541215 · Phase 3 1.8 mg nasopharyngitis 3.8% (placebo 27.9%) vomiting 3.8% (placebo 8.8%) abdominal pain 1.9% (placebo 7.4%) NCT01541215 · Phase 3 1.8 mg hyperglycaemia 2.1% (placebo 5.9%) pharyngitis 2.1% (placebo 5.9%) abdominal pain 0% (placebo 7.4%) NCT01541215 · Phase 3 abdominal distention 31.6% nausea 31.6% NCT03260881 · Phase 4 · registry result, not featured evidence nausea 25% (placebo 14.3%) NCT02765399 · Phase 4 · registry result, not featured evidence gi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nausea 29.1% NCT02014740 · Phase 4 · registry result, not featured evidence nausea 31.4% (placebo 19.4%) decreased in apetite 17.1% (placebo 11.1%) diarrhea 11.4% (placebo 8.3%) NCT01505673 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 16.3% decreased appetite 8.9% NCT01907854 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 12.4% lipase increased 8.4% NCT01973231 · Phase 4 · registry result, not featured evidence nausea 14.8% decreased appetite 10.9% diarrhoea 8.2% NCT02008682 · Phase 4 · registry result, not featured evidence vomiting 5.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination gastrointestinal disorders 27.1% (placebo 5.7%) general disorders and administration site conditions 2.9% (placebo 0%) nervous system disorders 2.9% (placebo 2.9%) NCT02889510 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence decreased appetite 14.4% diarrhoea 14.4% lipase increased 12.2% NCT03172494 · Phase 3 · registry result, not featured evidence nausea 37.2% (placebo 2.7%) diarrhea 17.9% (placebo 17.3%) allergic reaction to liraglutide 1.3% (placebo 0%) NCT01234649 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nausea 26.2% (placebo 6%) decreased appetite 9.4% (placebo 0%) diarrhoea 9.4% (placebo 3%) NCT02964247 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 34.4% constipation 13.9% diarrhoea 8.8% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence headache 12.5% (placebo 12.5%) asympomatic hyppglycaemia 6.3% (placebo 0%) nausea 6.3% (placebo 0%) NCT01937598 · Phase 3 · registry result, not featured evidence | j nausea 28.6% nasopharyngitis 15.4% diarrhoea 15.1% NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 31 more resultsnausea 20.2% (placebo 3.3%) headache 7.6% (placebo 8.2%) vomiting 6.7% (placebo 0%) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 nausea 24.2% (placebo 3.3%) headache 8.3% (placebo 8.2%) dizziness 7.5% (placebo 3.3%) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 nausea 21.7% (placebo 5.9%) hypoglycaemia 20.1% (placebo 18.3%) dizziness 8.5% (placebo 6.3%) NCT01147250 · Phase 3 hypoglycaemia 5.7% upper respiratory tract infection 5.7% NCT05114590 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 17.2% covid-19 13.4% nausea 12.1% NCT05413369 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.8% nausea 8.6% diarrhoea 5.5% NCT02787551 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.5% nausea 9.2% diarrhoea 7.3% NCT02787551 · Phase 3 · registry result, not featured evidence mild asymptomatic hypoglycaemia 33.3% hypercholesterolaemia 22.2% mild gastrointestinal complaints 22.2% NCT02168491 · Phase 3 · registry result, not featured evidence · combination nausea 10.4% nasopharyngitis 8.8% headache 5.8% NCT02058160 · Phase 3 · registry result, not featured evidence nausea 9.6% diarrhoea 9% upper respiratory tract infection 7% NCT02058147 · Phase 3 · registry result, not featured evidence nausea 25% (placebo 7.5%) hypoglycaemia 17% (placebo 10.3%) diarrhoea 10.8% (placebo 7.5%) NCT01798706 · Phase 3 · registry result, not featured evidence hypoglycaemia 35.9% nausea 25.2% blood glucose decreased 20.1% NCT01768559 · Phase 3 · registry result, not featured evidence nausea 15.5% headache 7.1% nasopharyngitis 7.1% NCT01517412 · Phase 3 · registry result, not featured evidence nausea 14.7% nasopharyngitis 9.8% hypoglycaemia 6.7% NCT01517412 · Phase 3 · registry result, not featured evidence nausea 16.3% (placebo 2.6%) hypoglycaemia 9.2% (placebo 4.6%) dizziness 8.7% (placebo 4.1%) NCT01169779 · Phase 3 · registry result, not featured evidence hypoglycaemia 27.4% (placebo 19.3%) nausea 27.4% (placebo 4.9%) headache 9.9% (placebo 3.6%) NCT00975286 · Phase 3 · registry result, not featured evidence nausea 26% (placebo 13.7%) nasopharyngitis 16.4% (placebo 14.9%) headache 13.3% (placebo 11.8%) NCT00763815 · Phase 3 · registry result, not featured evidence nausea 24.7% (placebo 10.6%) headache 16.5% (placebo 23.5%) vomiting 15.7% (placebo 3.5%) NCT00712673 · Phase 3 · registry result, not featured evidence nausea 25.1% (placebo 10.6%) headache 19.2% (placebo 23.5%) diarrhoea 15.3% (placebo 11.8%) NCT00712673 · Phase 3 · registry result, not featured evidence nausea 17.7% headache 12.7% diarrhoea 8.9% NCT00976937 · Phase 3 · registry result, not featured evidence hypoglycaemia 42.1% (placebo 40.7%) nausea 29.3% (placebo 9.6%) headache 12.5% (placebo 10.2%) NCT00715624 · Phase 3 · registry result, not featured evidence nausea 28% (placebo 8.8%) hypoglycaemia 24.4% (placebo 19.3%) nasopharyngitis 15.9% (placebo 20.4%) NCT00713830 · Phase 3 · registry result, not featured evidence nausea 37.9% (placebo 8.1%) vomiting 18% (placebo 0.6%) diarrhoea 14.9% (placebo 13.1%) NCT00763451 · Phase 3 · registry result, not featured evidence nausea 29.2% (placebo 8.1%) vomiting 13% (placebo 0.6%) headache 12.4% (placebo 12.5%) NCT00763451 · Phase 3 · registry result, not featured evidence nausea 50% nasopharyngitis 36.1% decreased appetite 19.4% NCT00905255 · Phase 3 · registry result, not featured evidence nausea 36.4% nasopharyngitis 27.3% decreased appetite 18.2% NCT00905255 · Phase 3 · registry result, not featured evidence hypoglycaemia 43.5% (placebo 23.6%) nausea 39.6% (placebo 4.5%) vomiting 18.2% (placebo 1.9%) NCT00866658 · Phase 3 · registry result, not featured evidence 20 µg decreased appetite 18.8% nausea 18.8% nasopharyngitis 12.5% NCT01596504 · Phase 2 · registry result, not featured evidence nausea 7.5% nasopharyngitis 5.6% headache 5% NCT01476475 · Phase 2 · registry result, not featured evidence nausea 22.1% decreased appetite 18.2% headache 11.7% NCT01175473 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 32 weeks versus 24 weeks.
- eThe reported result categories differ.
- fTrial phases differ: Phase 4 versus Phase 3.
- gAssessment timepoints differ: 26 weeks versus 24 weeks.
- hTrial phases differ: Phase 3 versus Phase 2.
- iAssessment timepoints differ: 52 weeks versus 8 weeks.
- jPopulation comparability has not been reviewed for 32 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liraglutide (Victoza)
show 1 more result
show 8 more results
show 7 more results
show 3 more results
show 1 more result
show 8 more results
+ 118 further endpoints in the CSV export.
lixisenatide
show 15 more results
show 8 more results
show 1 more result
show 6 more results
show 6 more results
show 3 more results
show 3 more results
show 3 more results
+ 62 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Victoza)'s landscape · lixisenatide's landscape